PulseSight Therapeutics receives CTA approval from ANSM for Phase I trial in France of PST-611, Transferrin Vectorized Therapy for dry AMD/Geographic Atrophy
PulseSight Therapeutics reinforces its scientific leadership in ophthalmology with the establishment of an International Scientific and Clinical Advisory Board
PulseSight Therapeutics Launches to Advance Non-viral Gene Therapies with Disruptive Minimally-Invasive Delivery Technology for Severe Retinal Diseases